IceCure Medical Ltd. (TASE: ICCM) announced today that Epoch Investment Partners, Inc. acquired 57% of its shares and certain voting rights for NIS 21.2 million.
IceCure Medical Ltd operates as a medical device company that develops and markets minimally-invasive and office-based cryoablation treatment solutions for women’s health. It provides IceSense3, a cryoablation system that uses an ultrasound imaging for the treatment of symptomatic breast fibroadenoma.
The company was founded in 2006 and is based in Caesarea, Israel.
Cryoablation is a technology that uses very low temperatures to ablate tissues (tumors). There are several advantages for using cryoablation for breast cancer treatment compared with the traditional surgery. Cryoablation is done in a physician’s office with local anesthesia under ultrasound guidance. In addition, since the procedure does not involve real tissue removal, the cosmetic effect is minimal with very small or no scars. Cryoablation is also less expensive than traditional surgeries that are much more expensive.